194 related articles for article (PubMed ID: 33989683)
21. Long-term evaluation of vitreomacular traction disorder in spectral-domain optical coherence tomography.
Odrobina D; Michalewska Z; Michalewski J; Dzięgielewski K; Nawrocki J
Retina; 2011 Feb; 31(2):324-31. PubMed ID: 21416651
[TBL] [Abstract][Full Text] [Related]
22. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
Manousaridis K; Peter-Reichart S; Mennel S
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1907-1916. PubMed ID: 28681138
[TBL] [Abstract][Full Text] [Related]
23. COMBINED PNEUMATIC AND ENZYMATIC VITREOLYSIS FOR SEVERE CASES OF VITREOMACULAR TRACTION.
Yu G; Seto BK; Yamada K; Zeng K; Arroyo JG
Retin Cases Brief Rep; 2022 Sep; 16(5):631-636. PubMed ID: 32910027
[TBL] [Abstract][Full Text] [Related]
24. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
[TBL] [Abstract][Full Text] [Related]
25. CLOSURE OF IDIOPATHIC FULL-THICKNESS MACULAR HOLE AFTER INTRAVITREAL C3F8 INJECTION WITHOUT VITREOMACULAR TRACTION RELEASE: A CASE REPORT AND REVIEW OF LITERATURE.
Fazel F; Rezaeian-Ramsheh A; Fazel M; Ahmadieh H
Retin Cases Brief Rep; 2024 Jan; 18(1):77-79. PubMed ID: 35993722
[TBL] [Abstract][Full Text] [Related]
26. Anatomical configurations of vitreomacular traction syndrome: influence on clinical course and surgical outcomes.
Lee EK; Lee SY; Lee JY; Heo JW; Yu HG; Chung H
Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1631-1639. PubMed ID: 31104140
[TBL] [Abstract][Full Text] [Related]
27. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
[TBL] [Abstract][Full Text] [Related]
28. COMPARING INTRAVITREAL AIR AND GAS FOR THE TREATMENT OF VITREOMACULAR TRACTION.
Gruchociak S; Djerada Z; Afriat M; Chia V; Santorini M; Denoyer A; Arndt C
Retina; 2020 Nov; 40(11):2140-2147. PubMed ID: 31876891
[TBL] [Abstract][Full Text] [Related]
29. Morphological Reconstitution and Persistent Changes After Intravitreal Ocriplasmin for Vitreomacular Traction and Macular Hole.
Zandi S; Freiberg F; Vaclavik V; Pfister IB; Traine PG; Kaya C; Michels S; Garweg JG
J Ocul Pharmacol Ther; 2020 Mar; 36(2):126-132. PubMed ID: 31934816
[No Abstract] [Full Text] [Related]
30. A retrospective cohort study in patients with tractional diseases of the vitreomacular interface (ReCoVit).
Stalmans P
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):617-28. PubMed ID: 26899900
[TBL] [Abstract][Full Text] [Related]
31. Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study.
Greven MA; Garg S; Chiu B; Shah SP; Wolfe J; Fine HF; Roth DB; Robinson J; Mong J; Hsu J; Regillo C; Ho A; Haller JA
Br J Ophthalmol; 2016 Sep; 100(9):1211-5. PubMed ID: 26659344
[TBL] [Abstract][Full Text] [Related]
32. Impact of phacoemulsification on posterior vitreous detachment formation in eyes with vitreomacular traction.
Tieger MG; Vavvas DG
Digit J Ophthalmol; 2023; 29(2):26-30. PubMed ID: 37727466
[TBL] [Abstract][Full Text] [Related]
33. Ocriplasmin for symptomatic vitreomacular adhesion.
Neffendorf JE; Kirthi V; Pringle E; Jackson TL
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD011874. PubMed ID: 29040800
[TBL] [Abstract][Full Text] [Related]
34. ANATOMICAL AND FUNCTIONAL OUTCOMES OF SYMPTOMATIC IDIOPATHIC VITREOMACULAR TRACTION: A Natural History Study From the Pan American Collaborative Retina Study Group.
Wu L; Zas M; Berrocal MH; Arevalo JF; Figueroa M; Rodriguez F; Serrano M; Graue F; Alezzandrini A; Gallego-Pinazo R; Roca JA; Iglicki M; Dalma-Weishauz J; Kozak I; Collado A; Badal J; Maia M; Salcedo-Villanueva G; Quiroz-Mercado H; Fromow-Guerra J; Lozano-Rechy D; Avila M; Chhablani J
Retina; 2016 Oct; 36(10):1913-8. PubMed ID: 26966868
[TBL] [Abstract][Full Text] [Related]
35. Vitreomacular traction quantitative cutoffs for the assessment of resolution after ocriplasmin intravitreal treatment.
Arrigo A; Calamuneri A; Bordato A; Aragona E; Pierro L; Bandello F; Battaglia Parodi M
Sci Rep; 2020 Oct; 10(1):17583. PubMed ID: 33067537
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal injection of expansile perfluoropropane (c(3)f(8)) for the treatment of vitreomacular traction.
Rodrigues IA; Stangos AN; McHugh DA; Jackson TL
Am J Ophthalmol; 2013 Feb; 155(2):270-276.e2. PubMed ID: 23164159
[TBL] [Abstract][Full Text] [Related]
37. Different modes of full-thickness macular hole formation.
Bringmann A; Unterlauft JD; Barth T; Wiedemann R; Rehak M; Wiedemann P
Exp Eye Res; 2021 Jan; 202():108393. PubMed ID: 33301774
[TBL] [Abstract][Full Text] [Related]
38. Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
Hager A; Seibel I; Riechardt A; Rehak M; Joussen AM
Br J Ophthalmol; 2015 May; 99(5):635-8. PubMed ID: 25403647
[TBL] [Abstract][Full Text] [Related]
39. The Portuguese Experience with Ocriplasmin in Clinical Practice.
Figueira J; Martins D; Pessoa B; Ferreira N; Meireles A; Sampaio A; Carneiro Â; Vaz F; Nascimento J; Moreno N; Roque J; Domingues M; Flores R; Teixeira C; Conde E; Henriques F; Proença H; Pita Negrão J; Barbosa M; Silva R; Vaz-Pereira S; Pereira Neves P; Gomes N; Raimundo M;
Ophthalmic Res; 2016; 56(4):186-192. PubMed ID: 27438077
[TBL] [Abstract][Full Text] [Related]
40. [Diseases of the vitreo-macular interface].
Koerner F; Garweg J
Klin Monbl Augenheilkd; 1999 May; 214(5):305-10. PubMed ID: 10420374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
